Generated by AI
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and other unmet medical needs. The company’s portfolio centers on treatments for sleep-wake disorders and related neurological conditions, with a strong emphasis on patients whose options remain limited. Its marketed therapy, WAKIX, is designed for the treatment of excessive daytime sleepiness in adults with narcolepsy, reflecting the company’s focus on specialized neuroscience care. Harmony Biosciences also advances research programs in adjacent rare neurological and endocrine disorders, combining commercial operations with clinical development capabilities. Headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences plays a focused role in the biopharmaceutical market by addressing niche patient populations through targeted, science-driven therapies.
Website630 West Germantown Pike
Plymouth Meeting, PA, 19462
United States
The latest articles about HRMY.
Summary of Feb 25's posts. Generated by AI.
Summary of Aug 14's posts. Generated by AI.
Summary of Jan 30's posts. Generated by AI.
Investors talking about HRMY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.